Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 7th of October for the Labour Day public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12617001174370
Ethics application status
Approved
Date submitted
20/07/2017
Date registered
10/08/2017
Date last updated
24/03/2024
Date data sharing statement initially provided
16/01/2020
Type of registration
Prospectively registered
Titles & IDs
Public title
Use of parental stem cells for children requiring a bone marrow transplant
Query!
Scientific title
TCR a+ß+/CD19+ cell depleted haploidentical donor stem cell transplantation for paediatric patients
Query!
Secondary ID [1]
292442
0
Nil known
Query!
Universal Trial Number (UTN)
U1111-1199-3727
Query!
Trial acronym
Paßlo (Paediatric aß haploidentical transplantation)
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Haematological malignancy
304053
0
Query!
Bone marrow failure
304145
0
Query!
Primary immunodeficiency
304225
0
Query!
Inherited metabolic disorder
304226
0
Query!
Condition category
Condition code
Cancer
303379
303379
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Cancer
303384
303384
0
0
Query!
Children's - Other
Query!
Human Genetics and Inherited Disorders
303576
303576
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Arm 1 - Group receiving investigational device
Patients will receive a TCR a+ß+/CD19+ cell depleted graft from a haploidentical parental donor. Candidates will only be eligible for Arm 1 of the study if there are no suitable human leucocyte antigen (HLA) matched readily available donors, and no suitably matched umbilical cord blood units available.
Conditioning therapy used will be dependent on HSCT indication. GVHD prophylaxis will include in vivo serotherapy (ATG) (once daily IV dose of 5mg/kg for 3 days) and mycophenolate mofetil in non-malignant patients (15mg/kg 3 times a day -2 to day +30, given initially IV with an option to switch to orally dependent on patient tolerability).
Donor product will be peripheral blood stem cells collected via G-CSF stimulated apheresis. Apheresis will be performed as per FACT guidelines, national standards and individual institution protocols. All donor products will be processed in FACT accredited Bone Marrow Transplant laboratories. Fresh donor product will undergo TCR aß+ depletion and CD19+ depletion using Miltenyi CliniMACS® paramagnetic bead technology. The target CD34+ dose will be 10 x10^6/kg recipient weight, with a recommended minimal dose of 5 x 10^6/kg.
Patients on Arm 1 will be assessed for neutrophil and platelet engraftment, transplant related mortality, graft versus host disease, relapse and overall survival. They will also be assessed for immune reconstitution, economic and quality of life outcomes.
Arm 2 – Control group
Candidates for Arm 2 will be patients undergoing alternate donor HSCT, defined as any donor that is not an HLA matched sibling (e.g., volunteer donor, matched umbilical cord blood units).
Economic and Quality of Life outcomes will be measured for these patients post-transplant.
Query!
Intervention code [1]
298621
0
Treatment: Devices
Query!
Intervention code [2]
298812
0
Treatment: Other
Query!
Comparator / control treatment
HSCTs administered to the control group will not be a+ß+/CD19+ HSCTs. Patients will be undergoing alternate donor HSCT, defined as any donor that is not an HLA matched sibling (e.g., volunteer donor, matched umbilical cord blood units).
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
302764
0
Determine the incidence of donor derived neutrophil recovery post a+ß+/CD19+ HSCT (defined as an absolute neutrophil count >500 x10^6/L for 3 consecutive days).
Query!
Assessment method [1]
302764
0
Query!
Timepoint [1]
302764
0
Patients will undergo regular clinical assessment post HSCT as inpatients, and then be reviewed at a minimum of weekly in an outpatient setting for at least the first 100 days post transplant.
The incidence of donor derived neutrophil recovery post a+ß+/CD19+ HSCT will be assessed at day 28 post transplant.
Query!
Primary outcome [2]
302765
0
Evaluate the cost of a+ß+/CD19+ HSCT compared to other alternate donor HSCT.
This aspect of the study will assess the equipment, personnel and time resources involved for the acquisition and delivery of a donor product. For each activity, eCRFs will be utilised to collect data from each participating site for each patient on the time and personnel involved in the relevant activity, as well as the quantities of any relevant consumables used (e.g. G-CSF for donor cell mobilisation).
This aspect of the study will also assess post-transplant health service utilisation, which will be based on two key aspects:
1) The use of hospital services. This will be assessed via the completion of an eCRF at study sites for inpatient hospital procedures, and will collect information on the timing and reason for each hospitalisation.
2) The use of medical and pharmaceutical services. For this purpose, patients (or parents/guardians) will be consented to access their Medicare data to allow for information on their medical service use (MBS) and pharmaceutical services (PBS).
Query!
Assessment method [2]
302765
0
Query!
Timepoint [2]
302765
0
1. The initial 12 month within trial period
2. Subsequent patient follow-up (up to five years post HSCT)
Query!
Secondary outcome [1]
336942
0
Determine the incidence of platelet engraftment (defined as a platelet count >20 x109/L for 7 consecutive days without requiring transfusion).
Query!
Assessment method [1]
336942
0
Query!
Timepoint [1]
336942
0
To confirm platelet engraftment, patients will undergo regular clinical assessment post HSCT as inpatients, and then be reviewed at a minimum of weekly in an outpatient setting for at least the first 100 days post transplant.
The incidence of platelet engraftment will be assessed at 100 days post a+ß+/CD19+ HSCT.
Query!
Secondary outcome [2]
336943
0
The time to neutrophil and platelet engraftment in a+ß+/CD19+ HSCT will be evaluated by clinician definition and prospective data captured on the study database.
Query!
Assessment method [2]
336943
0
Query!
Timepoint [2]
336943
0
Patients will undergo regular clinical assessment post HSCT as inpatients, and then be reviewed at a minimum of weekly in an outpatient setting for at least the first 100 days post transplant.
Query!
Secondary outcome [3]
336944
0
Determine the incidence of graft versus host disease (GVHD) grade II-IV as per published criteria (1994 Consensus Conference on Acute GVHD Grading).
Query!
Assessment method [3]
336944
0
Query!
Timepoint [3]
336944
0
At 100 days days post a+ß+/CD19+ HSCT.
Query!
Secondary outcome [4]
336945
0
Determine the incidence of graft versus host disease (GVHD) grade III-IV as per published criteria (National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease).
Query!
Assessment method [4]
336945
0
Query!
Timepoint [4]
336945
0
At 100 days post a+ß+/CD19+ HSCT.
Query!
Secondary outcome [5]
336946
0
Determine transplant related mortality post a+ß+/CD19+ HSCT by review of data captured on the study database.
Query!
Assessment method [5]
336946
0
Query!
Timepoint [5]
336946
0
At 100 days and 365 days post a+ß+/CD19+ HSCT.
Query!
Secondary outcome [6]
336947
0
Determine the overall survival post a+ß+/CD19+ HSCT.
Query!
Assessment method [6]
336947
0
Query!
Timepoint [6]
336947
0
At 2 years post a+ß+/CD19+ HSCT.
Query!
Secondary outcome [7]
337553
0
Evaluate time to full immune reconstitution in a+ß+/CD19+ HSCT.
Immune reconstitution will be assessed by formal measurement of lymphocyte subsets, including TCR a+ß+ and TCR g+d+ cells. Immunoglobulin levels (IgG, IgM, IgA) will also be performed at the same time points.
Query!
Assessment method [7]
337553
0
Query!
Timepoint [7]
337553
0
At 1 month, 3 months, 6 months, 1 year and 2 years post HSCT.
Query!
Secondary outcome [8]
337554
0
Explore the pattern of chimerism post a+ß+/CD19+ HSCT (assessed by whole blood chimerism evaluation).
Query!
Assessment method [8]
337554
0
Query!
Timepoint [8]
337554
0
At day 30 post HSCT, and then further assessment at day 90, day 180, 1 year and 2 years post HSCT. Lineage specific chimerism, including myeloid, B cell, T cell and NK cell lineages will be performed from day 90 where possible.
Query!
Secondary outcome [9]
337591
0
Quality of Life post HSCT will be assessed via the Paediatric Quality of Life (CHU9D) questionnaire and the Pediatric Quality of Life Inventory (cancer module).
Query!
Assessment method [9]
337591
0
Query!
Timepoint [9]
337591
0
Questionnaires will be completed prior to transplant, at 3 months, 6 months, 12 months, and then annually until 5 years post transplant.
Query!
Secondary outcome [10]
337612
0
Carer burden post HSCT will be assessed via the Parent/Carer Impact Form (modified Work Productivity and Activity Impairment Questionnaire) (WPAI-GH) and the Care related Quality of Life (CarerQoL-7D) questionnaire.
Query!
Assessment method [10]
337612
0
Query!
Timepoint [10]
337612
0
Questionnaires will be completed prior to transplant, at 3 months, 6 months, 12 months, and then annually until 5 years post transplant.
Query!
Eligibility
Key inclusion criteria
A patient must meet the following criteria to be eligible for inclusion of Arm 1 of the study:
• Aged less than 18 years
• The availability of a HLA matched haploidentical donor greater or equal to 5/10
• Absence of readily available matched sibling donor
• Absence of other readily available non-related donors:
- Unrelated volunteer donors; HLA match less than 9/10
- UCB units with adequate cell dose; HLA match less than 5/6 on low resolution typing or HLA match less than 6/8 on high resolution typing (8/8 HLA match for non malignant patients)
• Adequate organ function
• Female patients of child bearing age are not pregnant
• Written consent of the patient’s legal guardian, and assent from the patient if age appropriate
All potential parent donors must undergo high resolution HLA typing, and assessment as to their fitness to undergo peripheral blood stem cell collection via G-CSF stimulated apheresis.
Query!
Minimum age
0
Years
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Patient has undergone HSCT within the last 180 days
• Evidence of HIV infection
• Current uncontrolled bacterial or fungal infection
• The treatment protocol in part or in its entirety is declined by either the patient or their legal guardian
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Date of first participant enrolment
Anticipated
1/09/2017
Query!
Actual
7/09/2018
Query!
Date of last participant enrolment
Anticipated
1/06/2024
Query!
Actual
15/02/2022
Query!
Date of last data collection
Anticipated
1/09/2024
Query!
Actual
Query!
Sample size
Target
94
Query!
Accrual to date
Query!
Final
62
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA,VIC
Query!
Recruitment hospital [1]
8547
0
Sydney Children's Hospital - Randwick
Query!
Recruitment hospital [2]
8548
0
The Children's Hospital at Westmead - Westmead
Query!
Recruitment hospital [3]
8549
0
Lady Cilento Children's Hospital - South Brisbane
Query!
Recruitment hospital [4]
8550
0
The Royal Childrens Hospital - Parkville
Query!
Recruitment hospital [5]
8551
0
Princess Margaret Hospital - Subiaco
Query!
Recruitment postcode(s) [1]
16644
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
16645
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
16647
0
3052 - Parkville
Query!
Recruitment postcode(s) [4]
16646
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
16648
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
9060
0
New Zealand
Query!
State/province [1]
9060
0
Auckland
Query!
Funding & Sponsors
Funding source category [1]
297015
0
Other Collaborative groups
Query!
Name [1]
297015
0
Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG)
Query!
Address [1]
297015
0
ANZCHOG Concept Validation Scheme
Hudson Institute
27-31 Wright Street
Clayton, VIC 3168
Query!
Country [1]
297015
0
Australia
Query!
Funding source category [2]
297043
0
Commercial sector/Industry
Query!
Name [2]
297043
0
Miltenyi Biotech
Query!
Address [2]
297043
0
Miltenyi Biotech GmbH
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach,
Germany
Query!
Country [2]
297043
0
Germany
Query!
Funding source category [3]
297044
0
Charities/Societies/Foundations
Query!
Name [3]
297044
0
Tour de Cure Ltd.
Query!
Address [3]
297044
0
Tour de Cure Ltd.
Suite 2 (Level 1),
Building B,
14 Rodborough Road,
Frenchs Forest NSW 2086
Query!
Country [3]
297044
0
Australia
Query!
Funding source category [4]
297084
0
Charities/Societies/Foundations
Query!
Name [4]
297084
0
Children's Cancer Foundation
Query!
Address [4]
297084
0
Level 4,
4 Freshwater Place,
Southbank VIC 3006
Query!
Country [4]
297084
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
Kids Oncology And Leukaemia TriAls (KOALA)
Query!
Address
Kids Cancer Centre,
Sydney Children’s Hospital,
High Street,
Randwick, NSW Australia 2031
Query!
Country
Australia
Query!
Secondary sponsor category [1]
296176
0
None
Query!
Name [1]
296176
0
Query!
Address [1]
296176
0
Query!
Country [1]
296176
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
298198
0
Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee (EC00175)
Query!
Ethics committee address [1]
298198
0
Queensland Children’s Hospital Precinct Level 7, 62 Graham Street South Brisbane QLD 4101
Query!
Ethics committee country [1]
298198
0
Australia
Query!
Date submitted for ethics approval [1]
298198
0
11/03/2017
Query!
Approval date [1]
298198
0
07/06/2017
Query!
Ethics approval number [1]
298198
0
HREC/17/QRCH/48
Query!
Summary
Brief summary
The primary purpose of this trial is to evaluate the efficacy of using parent donors for bone marrow transplants in children, using a particular processing method of the donor blood cells (TCR a+ß+/CD19+ cell depletion) compared to those receiving a standard bone marrow transplant from another donor, We also want to compare cost to the health system of TCR a+ß+/CD19+ cell depletion with that of standard bone marrow transplant procedures, Who is it for? Patients may be eligible to enrol in this trial if they are aged 3 months to 18 years of age, have been diagnosed with haematological malignancies or non malignant disorders requiring a bone marrow transplant, and have an eligible parent donor. Study details Patients who have no fully matched brothers or sisters, and no well matched volunteer donors or umbilical cord blood units available will receive a TCR a+ß+/CD19+ cell depleted graft from a parent donor. Control patients will receive a standard bone marrow transplant from another donor (e.g., volunteer donor) as per institutional practice. Patients will undergo clinical assessments at regular intervals for two years following the transplant to evaluate the efficacy of the treatment. Further information, such as quality of life and carer burden, will be collected for up to 5 years following the transplant. It is hoped that the findings from this trial will provide information on whether parent donor cells undergoing specialised cell processing can be effectively used for bone marrow transplants in children with haematological malignancies or non malignant disorders.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
76302
0
Dr Richard Mitchell
Query!
Address
76302
0
Kids Cancer Centre
Level 1, Sydney Children's Hospital
High St, Randwick, NSW 2031
Query!
Country
76302
0
Australia
Query!
Phone
76302
0
+612 9382 1690
Query!
Fax
76302
0
Query!
Email
76302
0
richard.mitchell@unsw.edu.au
Query!
Contact person for public queries
Name
76303
0
Laura Mitchell
Query!
Address
76303
0
Kids Cancer Centre
Level 1, Sydney Children's Hospital
High St, Randwick, NSW 2031
Query!
Country
76303
0
Australia
Query!
Phone
76303
0
+612 9382 3102
Query!
Fax
76303
0
Query!
Email
76303
0
laura.mitchell@health.nsw.gov.au
Query!
Contact person for scientific queries
Name
76304
0
Richard Mitchell
Query!
Address
76304
0
Kids Cancer Centre
Level 1, Sydney Children's Hospital
High St, Randwick, NSW 2031
Query!
Country
76304
0
Australia
Query!
Phone
76304
0
+612 9382 1690
Query!
Fax
76304
0
Query!
Email
76304
0
richard.mitchell@unsw.edu.au
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF